GlassScriptPhysician profile
Carol A Trakimas
NPI 1144396342
$13,109.25
in general payments reported to CMS, 2019-2025
37 companies · $2,760 in 2025
The $2,760 reported for 2025 was more than what 83% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $736 · 2020: $343 · 2021: $1,190 · 2022: $2,913 · 2023: $2,484 · 2024: $2,683 · 2025: $2,760.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,772 · Education: $155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,772.39 |
| Education | $154.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,822.44 | 2019-2025 | Skyrizi, Rinvoq, Humira |
| Sun Pharmaceutical Industries INC. | $1,215.42 | 2021-2025 | Ilumya, Blu-U |
| Janssen Biotech, INC. | $837.19 | 2021-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $831.16 | 2021-2025 | |
| Leo Pharma INC. | $807.65 | 2019-2025 | Adbry, Anzupgo |
| Merz North America, INC. | $748.59 | 2022-2025 | Xeomin |
| Pfizer INC. | $733.65 | 2022-2025 | |
| Genzyme Corporation | $723.87 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $483.51 | 2022-2025 | Sotyktu, Sprycel |
| Galderma Laboratories, L.P. | $471.34 | 2019-2025 | Nemluvio, Dysport, Aklief |
| Regeneron Healthcare Solutions, INC. | $464.30 | 2021-2025 | Dupixent, Libtayo |
| Almirall LLC | $379.10 | 2019-2022 | |
| Amgen INC. | $319.68 | 2020-2025 | Otezla, Otezla |
| Journey Medical Corporation | $272.12 | 2022-2023 | |
| Lilly USA, LLC | $245.09 | 2021-2024 | Taltz, Olumiant, Ebglyss |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $243.42 | 2021-2025 | Bimzelx |
| Dermavant Sciences, INC. | $205.98 | 2022-2024 | Vtama |
| Incyte Corporation | $185.54 | 2022-2025 | Opzelura |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $156.54 | 2019-2024 | Siliq, Targretin, Cabtreo |
| Epi Health, LLC | $150.16 | 2019-2022 | |
| Allergan, INC. | $124.79 | 2019-2022 | |
| Celgene Corporation | $108.05 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.88 | 2024-2025 | Spevigo |
| Prugen, INC. Pharmaceuticals | $72.72 | 2019-2020 | |
| Biofrontera INC. | $70.45 | 2021-2023 | Ameluz, Xepi, Bf-Rhodoled |
| Dermira, INC. | $59.68 | 2019-2020 | |
| Helsinn Therapeutics (U.S.), INC. | $55.44 | 2021-2023 | Valchlor |
| Genentech USA, INC. | $42.28 | 2022-2024 | Erivedge, Xolair |
| Mayne Pharma Commercial LLC | $40.08 | 2019 | |
| Arcutis Biotherapeutics, INC. | $32.59 | 2023 | |
| Verrica Pharmaceuticals INC. | $23.83 | 2024 | Ycanth |
| Organon LLC | $20.98 | 2025 | Vtama |
| Kyowa Kirin, INC. | $19.91 | 2021 | |
| Vyne Pharmaceuticals INC. | $17.32 | 2020 | |
| Aclaris Therapeutics, INC. | $16.83 | 2019 | |
| Pierre Fabre Pharmaceuticals, INC. | $16.29 | 2019 | |
| Lnhc, INC | $15.38 | 2025 | Zelsuvmi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carol Trakimas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.